You are here: Industry Insights > Breast Cancer

News List

Novartis' Kisqali garners FDA approval as first-line breast cancer treatment firstwordpharma
March 15, 2017
The FDA approved Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor positive, HER2-negative advanced or metastatic breast cancer.
Is Radiation Therapy Overused in Breast Cancer Care? drugs.com
March 15, 2017
More than half of older American women with early breast cancer may get more radiation therapy than needed, which significantly boosts medical costs, a new study indicates.
Potential drug candidates halt prostate and breast cancer growth worldpharmanews
March 10, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers.
German Community of Gynecological Oncology (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines b3cnewswire
March 09, 2017
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer
Phase III APHINITY study shows Roche's Perjeta® regimen helped people with an aggressive type of ear worldpharmanews
March 07, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) have announced positive results from the phase III APHINITY study.
Combination of Roche's Perjeta, Herceptin cuts disease recurrence, death in breast cancer study firstwordpharma
March 03, 2017
Roche announced Thursday that the Phase III APHINITY study met its primary endpoint, showing that adjuvant treatment with the combination of Perjeta (pertuzumab)...
AstraZeneca Phase III breast cancer trial met primary endpoint europeanpharmaceuticalreview
February 24, 2017
AstraZeneca announced positive results from its Phase III trial comparing Lynparza (olaparib) tablets to physician’s choice of a standard of care chemotherapy, in the treatment of patients with HER2-negative metastatic breast cancer, harbouring germline B
AstraZeneca’s Lynparza hits breast cancer trial targets pharmatimes
February 21, 2017
A late-stage study of AstraZeneca's PARP inhibitor Lynparza in patients with HER2-negative metastatic breast cancer who also carry BRCA1 or BRCA2 mutations has its primary target in boosting progression-free survival (PFS).
NICE recommends targeted breast cancer radiotherapy treatment europeanpharmaceuticalreview
February 09, 2017
The National Institute for Health and Care Excellence (NICE) has today published draft guidance recommending the Intrabeam Radiotherapy System (Carl Zeiss UK) for people with early breast cancer for controlled use with the collection of further data on it
When Loved One Has Breast Cancer, Partner Suffers, Too drugs.com
January 24, 2017
Breast cancer can take a heavy toll on the partners of patients, too, a new study finds.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page